search icon
      blog search icon

      What Is Hurting VVOS Stock In Premarket Session? - Stocks Telegraph

      By ST Staff

      Published on

      July 8, 2021

      1:02 PM UTC

      What Is Hurting VVOS Stock In Premarket Session? - Stocks Telegraph

      Pre-market trading showed shares of Vivos Therapeutics Inc. (VVOS) down by 10.58% at $4.65. Vivos stock closed the last session at $5.20, increasing 23.52% or $0.99. VVOS stock fluctuated between $4.42 and $5.45 during trading. During the day, 7.33 million shares of VVOS stock exchanged hands, exceeding the company’s normal 50-day daily volume of 0.15 million and exceeding its regular volume of 0.23 million for the year so far.

      In the past week, VVOS stock has moved up 7.66% while it has lost -15.72% in the past six months. VVOS stock has decreased -43.54% over the last three months, while so far this year it has returned -12.01%. In the last session, VVOS stock gained value on encouraging patient outcome news, but it seems profit taking has hurt the stock in the premarket session today.

      Why did the stock price of VVOS rise?

      Medical Technology Company Vivos develops and commercializes innovative diagnostics and treatment options for adult patients suffering from sleep disorders such as obstructive sleep apnea (OSA). In the Vivos treatment system for mild-to-moderate OSA, customized oral appliances and protocols are employed.

      According to VVOS, the Vivos System oral appliance technology is the first non-invasive, non-pharmacological, non-surgical, and cost-effective non-surgical treatment option for mild-to-moderate OSA. Adult and child orthodontic appliances are also available through VVOS. Over 1,200 dentists have successfully used VVOS’ oral appliances with more than 17,000 patients worldwide.

      According to Vivos, new data is available from an independent research study regarding its proprietary Vivos treatment for addressing dental tissue anomalies and dentofacial malformations which are associated with OSA and other debilitating conditions.

      Key findings of the data include:

      • The vast majority of OSA patients surveyed (97 percent) reported that the Vivos treatment had achieved their desired outcome.
      • More than half or 63% of respondents surveyed said their dentist provides them with the best advice on finding a lasting solution to OSA.
      • About one-third or 29% of patients surveyed reported searching for non-surgical treatment options for OSA.

      What VVOS offers?

      Patients are frequently seeking a significant reduction in OSA and related symptoms with Vivos (VVOS), as CPAP satisfaction and compliance rates remain low. The VVOS noted that some studies show CPAP usage rates of 30 to 60 percent and that OSA may become chronic, life-threatening comorbidities if untreated. Vivos treatment, on the other hand, typically takes 12 to 24 months to complete, after which patients no longer require ongoing treatment.

      More From Stocks telegraph